Long-acting beta2-agonists in addition to inhaled corticosteroids in chronic asthma
20 results
1 - 20
Long-acting beta2-agonists in addition to inhaled corticosteroids in chronic asthma 
Addition of long‐acting beta2‐agonists to inhaled corticosteroids for chronic asthma in children- Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children: Cochrane systematic review
- Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children
- Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma: Cochrane systematic review
- Addition to inhaled corticosteroids of long‐acting beta2‐agonists versus anti‐leukotrienes for chronic asthma
- Long‐acting beta2‐agonists as an inhaled corticosteroid‐sparing agent for chronic asthma in adults and children
- Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta‐analysis
- Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma
- Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid: Cochrane systematic review
- Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma
- Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease